Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

NCT03576443 | Completed Phase 2

• 1 other identifier: NLG-LBC-07
• Study Type: interventional
• Target: 36
• Locations: 2 countries
• Sites: 6

Brief Summary

Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly of the GCB subtype. Possibly, the efficacy may be related to the presence of specific mutations within the B-cell receptor pathway.

Conditions

Diffuse Large B Cell Lymphoma

Outcome Measures

Primary Outcomes (1)

• Overall response rate for GCB DLBCL

  Overall response rate (ORR) for GCB DLBCL

  at time of progression, up to 112 weeks from start of treatment

Study Arms (1)

Treatment arm

EXPERIMENTAL

Idelalisib 150 mg x 2 p o, until progression

Drug: Idelalisib

Interventions

Idelalisib DRUG

Idelalisib 150 mg x 2 p o

Treatment arm

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>18 years.
• Histologically confirmed diffuse large B-cell lymphoma (DLBCL) , including transformed low grade lymphoma, with either:
• Refractory disease: defined as disease progression while receiving their most recent prior cytotoxic chemotherapy (single-agent immunotherapy as maintenance is not considered cytotoxic therapy).
• Persistent disease: defined as stable disease or partial response at the completion of their most recent prior cytotoxic chemotherapy.
• Relapsed/recurrent disease: defined as complete response at the end of their most recent prior cytotoxic chemotherapy with subsequent relapse or disease recurrence.
• Subjects must have received prior rituximab and may have received up to 5 prior regimens containing cytotoxic chemotherapies.
• Subjects must not be candidates for high-dose chemotherapy with autologous stem cell support (ASCT), due to one or more of the following factors: relapse after high dose chemotherapy, age, comorbid disease, performance status, or persisting toxicities from prior chemotherapy.
• Absolute neutrophil count (ANC) \>1.0 x 109/L, unless related to bone marrow infiltration.
• At least 1 measurable disease lesion that is \>1.0 cm in 2 perpendicular dimensions, with the product diameter \>2.25 cm2 by computed tomography (CT) or magnetic resonance imaging (MRI).
• Negative serum pregnancy test within 1 week before first treatment if the subject is a woman of childbearing potential. The use of highly-effective contraception methods\* are required during the study for women of child-bearing potential. Due to the toxicity of idelalisib, women who will use a hormonal contraceptive must in addition also use a barrier method, since it is currently unknown whether idelalisib may reduce the effectiveness of hormonal contraceptives. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
• WHO performance status 0 - 3.
• Written informed consent.

You may not qualify if:

• Prior allogeneic hematopoietic stem cell transplant (HSCT).
• Prior treatment with PI3K inhibitors.
• Serum total bilirubin ≥ 1.5 x ULN (unless elevated due to Gilbert's syndrome).
• Serum ALT and AST ˃ 2.5 x ULN.
• Estimated Creatinine Clearance \< 10 ml/min.
• Known seropositivity for human immunodeficiency virus (HIV).
• Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension.
• Known history of drug induced pneumonitis.
• On-going inflammatory bowel disease.
• Evidence of serious active infection (eg, requiring an intravenous \[IV\] antibiotic, antiviral, or antifungal agent), or subjects with a recent history of deep tissue infections such as fascitis or osteomyelitis.
• Chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational drugs/devices \<10 days before first dose of investigational product in this study. Subjects receiving high doses of corticosteroids must have been tapered to a stable dose at least 7 days before the first dose of investigational product.
• Pregnant or breastfeeding women.
• Symptomatic central nervous system (CNS) NHL; a lumbar puncture is not required unless CNS involvement with NHL is clinically suspected.
• Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition).
• Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for \>2 years.

Sponsors & Collaborators

• Nordic Lymphoma Group: lead

Study Sites (6)

Aarhus University Hospital

Aarhus C, 8000, Denmark

Location

Odense University Hospital

Odense, Denmark

Location

Halmstad County Hospital

Halmstad, 30 233, Sweden

Location

Linkoping University Hospital

Linköping, 581 85, Sweden

Location

Skane University Hospital

Lund, 221 85, Sweden

Location

Karolinska University Hospital

Stockholm, 141 86, Sweden

Location

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

idelalisib

Condition Hierarchy (Ancestors)

Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Mats Jerkeman

  Department of Oncology Skåne University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2018
• First Posted: July 3, 2018
• Study Start: July 7, 2017
• Primary Completion: September 30, 2021
• Study Completion: September 30, 2021
• Last Updated: October 13, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

SE (4); DK (2)